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Neuronal ceroid lipofucinoses (NCLs) are a group of severe neurodegenerative disorders characterized by accumulation of autofluorescent
ceroid lipopigment in patients' cells. The different forms of NCL share many similar pathological features but result from mutations in different
genes. The genes affected in NCLs encode both soluble and transmembrane proteins and are localized to ER or to the endosomes/lysosomes.
Due to selective vulnerability of the central nervous system in the NCL disorders, the corresponding proteins are proposed to have important,
tissue specific roles in the brain. The pathological similarities of the different NCLs have led not only to the grouping of these disorders but also
to suggestion that the NCL proteins function in the same biological pathway. Despite extensive research, including the development of several
model organisms for NCLs and establishment of high-throughput techniques, the precise biological function of many of the NCL proteins has
remained elusive. The aim of this review is to summarize the current knowledge of the functions, or proposed functions, of the different NCL
proteins.
© 2006 Published by Elsevier B.V.Keywords: Batten disease; Lysosomal degradation; NCL; Neurodegeneration; Storage disease1. Introduction
Neuronal ceroid lipofucinoses (NCLs) are a group of severe
neurodegenerative disorders affecting up to 1: 12,500 live births
worldwide. Although certain forms of NCL are rare and concen-
trated regionally, as a whole the NCLs are considered to be
among the most common hereditary dementing illnesses of
childhood. NCL disorders are characterized by massive accu-
mulation of autofluorescent lipopigment in patients' tissues.
Lysosomal inclusions are seen as granular osmiophilic deposits
(GRODs), curvilinear, fingerprint, or rectilinear profiles upon
electron microscopic analysis. The central nervous system is the
most dramatically affected organ; however, the accumulation of
the autofluorescent material is ubiquitous, and in most forms of
NCL subunit c of mitochondrial ATP synthase constitutes a large
part of the proteinaceous component of storage bodies. NCL⁎ Corresponding author. Tel.: +3589 47448976; fax: +3589 47448480.
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doi:10.1016/j.bbadis.2006.05.007brains showmassive neuronal cell atrophy and neuronal cell loss
(reviewed in [1–3]). Clinical symptoms of NCLs include loss of
vision, epilepsy, progressive mental retardation and a reduced
lifespan.
NCL disorders result from mutations in different CLN genes
(CLN1–CLN9). Six of these genes have been cloned (CLN1–3,
5, 6, and 8) and these encode both soluble and transmembrane
proteins located in either endosomes/lysosomes or the ER
(reviewed in [4]). (CLN4, which encodes the autosomal domi-
nant form of adult NCL, CLN7, a Turkish variant late infantile
NCL, and CLN9, found in Serbian and German patients, have
yet to be identified). More recently, the group of NCL disorders
has been expanded to encompass disorders or protein deficien-
cies with highly similar pathological findings to “classical”
human NCLs. These include deficiencies of the lysosomal as-
partyl proteinase cathepsin D [5–9] and other cathepsins [10–
12]. Defects in members of the ClC chloride channel family
have also been shown to share pathological findings character-
istic of NCLs [13,14].
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unknown. The heterogeneity of the NCL proteins and diversity
in their subcellular localizations suggests that they may play
roles in a common functional pathway especially important in
neuronal cells. Cell biological studies, characterization of model
organisms, and development of high throughput screening me-
thods have shed light on potentially important functional path-
ways. The results of these studies are discussed in this review.
1.1. CLN1 (Palmitoyl-protein thioesterase)
The infantile form of NCL (CLN1 disease) is caused by
severe deficiency in the lysosomal enzyme, palmitoyl protein
thioesterase (PPT1) [15]. PPT1 is an enzyme that removes fatty
acids in covalent linkage to cysteine residues in proteins [16,17],
ensuring the eventual metabolic disposal of S-acylated cysteine
residues during lysosomal degradation [18,19]. A role for PPT1
in the fatty acylation cycle of cytosolic signaling molecules has
not been convincingly demonstrated; this function appears to be
performed by another enzyme, acyl-protein thioesterase (APT)
[20]. A homolog of PPT1, PPT2, is a lysosomal fatty acyl
thioesterase that hydrolyzes palmitoyl-CoA but not palmitoyl-
cysteine [21,22]. No case of human PPT2 deficiency has been
described, although deficiency in PPT2 causes an NCL-like
disorder with unusual visceral features in mice [23].
The fatty acyl thioesterase activity of PPT1 was first described
in relation to its ability to cleave palmitate from a model palmi-
toylated substrate, H-Ras. The enzyme was purified by classical
techniques from bovine brain (33,000-fold) using [3H]palmitoyl
H-Ras as a substrate [16,24]. [3H]palmitate was shown to be a
product of the cleavage reaction. The enzyme is effectively
inhibited by the histidine-modifying reagent, diethyl pyrocarbo-
nate, but not by phenylmethanesulfonyl fluoride (PMSF), which
modifies serine. Resistance to PMSFwas later shown to be due to
steric hindrance around the active site serine, as PPT1 is a serine
hydrolase [25]. The enzyme is stabilized by EDTA and inacti-
vated by heavymetal contamination of buffers, presumably due to
the presence of a vicinal disulfide bridge critical for the structural
integrity of the enzyme. In addition to palmitoylated Ras, the
enzyme was shown to remove palmitate from the subunits of
modified Gα proteins, a number of other proteins, and from pal-
mitoyl-CoA.No phospholipase C, phospholipase A2, triglyceride
or diglyceride lipase activity was detected [16].
PPT1 is encoded by a 25-kb gene containing nine exons on
human chromosome 1p32, which produces a single 2.5 kb mes-
senger RNA [26]. The encoded protein contains a signal peptide,
which is cleaved co-translationally. The mature protein migrates
as a 37/35-kDa doublet and is reduced to 31-kDa upon degly-
cosylation [27]. The amino terminal sequence of the purified
native protein, Asp–Pro–Pro–Ala–Pro… differs from the amino
terminus of the recombinant protein produced in Sf9 cells (His–
Leu–Asp–Pro–Pro–Ala–Pro…), indicating the action of dipep-
tidyl aminopeptidase during processing in the lysosome [16,24].
PPT1 contains three asparagine-linked glycosylation sites, all of
which are utilized and contribute to enzyme activity and/or sta-
bility [28]. Lysosomal targeting of the enzyme through the
classical mannose 6-phosphate receptor pathway has been de-monstrated in peripheral tissue [27,29,30] and the enzyme has
been identified in a proteomic study of mannose 6-phosphate
binding proteins in brain [31]. Proteomic studies have also
identified PPT1 as a prominent component of placental lyso-
somes [32] and macrophage phagosomes [33].
The X-ray crystallographic structure of PPT1 has been
determined [28]. The enzyme is a classical α/β serine hydrolase
consisting of twomajor domains with a fatty acid binding groove
down the center of the enzyme. The catalytic triad consists of
Ser115, Asp233, and His289. The structure of the covalent fatty
acyl-enzyme intermediate shows the palmitate bound in an
extended conformation along a hydrophobic groove in the se-
cond domain of PPT1. There is no evidence for a movable lid
that regulates the interfacial behavior of many lipases [34].
The role of PPT1 in themetabolism of lipid-modified proteins
has been demonstrated through metabolic labeling studies
[18,19]. Cell lines from patients deficient in PPT1 were labeled
with [35S]cysteine and small lipophilic compounds migrating as
small peptides were demonstrated by thin-layer chromatogra-
phy. The formation of these compounds was blocked by protein
synthesis inhibitors and by inhibitors of lysosomal metabolism,
demonstrating that they were derived from lipid-modified pro-
teins in the process of lysosomal degradation.
How PPT1 deficiency leads to selective central nervous sys-
tem degeneration is unclear. The storage material is widespread,
and virtually every organ displays storage material. This suggests
a selective vulnerability of neurons, presumably enhanced by the
post-mitotic nature of neurons and their limited turnover. Tran-
script expression profiling (microarray) studies on whole brain
indicate up-regulation of genes associated with the inflammatory
response in INCL [35] and in other lysosomal storage disorders
affecting the brain [36–39]. It is conceivable that signals produced
by distressed post-mitotic cells (neurons) provoke this inflam-
matory response, but the nature of such signals remains to be
determined. Of note, not all neurons in the central nervous system
may be equally vulnerable. Detailed studies of neuronal loss in
PPT1 knockout mice have shown selective drop-out of GABA-
ergic interneurons of the hippocampus early in the course of the
disorder [40].
Saposins A and D have been identified as major protein
components of the granular osmiophilic bodies [41], but neither
protein is a substrate for PPT, as they are not S-acylated. In
addition, saposin D accumulates to a high degree (10–20-fold)
when normal lymphoblasts are cultured in the presence of
lysosomotropic aminothiols [42], suggesting that saposin accu-
mulation may be an interesting but secondary marker for lyso-
somal dysfunction.
Selective apoptosis of neurons has been observed patholo-
gically in humans and in animal models of INCL, prompting
studies of the effect of PPT on apoptosis in cell culture models
[43–47]. These studies have shown a tendency for decreased
PPT activity to correlate with increased sensitivity to apoptosis
induced by selected agents, particularly C2-ceramide, whereas
overexpression of PPT was associated with decreased sensitiv-
ity. The conclusions that can be drawn from these studies are
limited by the use of highly overexpressed, tagged versions of
PPT (with concerns about correct localization), use of
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inhibition of PPT activity through the use of antisense RNA.
Furthermore, overexpression of PPT in the developing Droso-
phila eye has yielded a contradictory result showing increased,
rather than decreased apoptosis [48]. Thus, the effect of PPT on
apoptosis may be highly context-dependent.
Neuronal cultures have provided another avenue for explo-
ration. While PPT1 can be regarded as a classical lysosomal
enzyme in extraneuronal tissues, the subcellular localization of
PPT1 in neurons is somewhat unclear. Localization to synaptic
vesicles has been suggested by several studies [49–51]. PPT1 is
found in synaptic vesicles in neuronal cultures when overex-
pression is driven through viral transfection [49–51]. However,
no evidence for synaptic vesicle localization was found under
conditions of endogenous expression [52].
Cultured neurons from PPT1 knockout mice have been
shown to develop a decrease in the number of synaptic vesicles
per bouton with time [52]. Three lines of evidence supported this
finding: (1) a progressive decrease in synaptic miniature poten-
tials of 45% up to 25 days in culture; (2) a decrease in synaptic
vesicle release of 30–40% as determined by fluorescent dye
studies. Both the total and rapid releasable pool were affected;
(3) concomitant decline in the number of vesicles per bouton
visualized by electron microscopy. A number of passive and
active membrane properties of the neurons were normal, inclu-
ding resting membrane potential, membrane resistance, action
potential amplitude and action potential half-width. No increase
in apoptosis in the knockout cells was seen over 25 days in
culture, indicating that the decline in synaptic vesicle number per
bouton was a specific and early finding. Neuronal lysosomal pH
was also found to be abnormally elevated. These intrinsically
abnormal properties of neurons could potentially explain key
features of the clinical disease, such as myoclonus and seizures.
The availability of mouse models of PPT1 deficiency has
provided the opportunity to explore disease pathogenesis in even
more detail [35,53]. Recently, the unfolded protein response
(UPR) has been implicated in the neuropathology of PPT1
deficiency [54]. A crucial event in the UPR is the phosphoryla-
tion of translation initiation factor, eIF2α, which mediates global
translation suppression and promotes up-regulation of stress-
induced genes (reviewed in [55, 56]). Increased levels of
phosphorylated eIF2a, as well as marked upregulation of two
stress-induced genes (ATF3 and XBP-1), were demonstrated.
Strikingly increased immunostaining for Grp78/BiP, an ER
marker, was shown, and an abnormal distribution of over-
expressed palmitoylated proteins in PPT-deficient fibroblasts
was reported (though no non-palmitoylated protein controls
were included, so it is unclear whether the phenomenon is
specific to palmitoylated proteins). Activation of the initiator
caspase (caspase-12) and effector caspase (caspase-3) was seen.
These data are supported by data from another laboratory
showing activation of the UPR in another lysosomal enzyme
deficiency state, GM1 gangliosidosis [57].
In summary, PPT1 deficiency is the underlying cause of
INCL, but the intervening steps between enzyme deficiency and
selective neurodegeneration remain to be determined. Inflam-
matory mediators, quantitative synaptic vesicle defects, abnorm-alities of lysosomal pH regulation and induction of the unfolded
protein response, may all contribute to the eventual outcome.
1.2. CLN2 (Tripeptidyl peptidase-I)
Severe deficiency in the enzyme tripeptidyl peptidase-I (TPP I)
underlies classical late infantile NCL [58–61]. The defect was
discovered through a proteomics approach that led to the iden-
tification of a lysosomal protein that was missing in LINCL brain
specimens. The protein shared homologywith bacterial pepstatin-
insensitive proteases, and was later found to be identical to
tripeptidyl aminopeptidase that had been purified to homogeneity
from rat spleen [62]. It is one of two enzymes in mammalian cells
that can “count to three” (reviewed in [63]), that is, it can remove
three amino acids (as one unit) from the amino terminus of
proteins. Like PPT1 (CLN1), TPP I is a lysosomal enzyme with
an acidic pH optimum that is targeted to the lysosome through the
mannose 6-phosphate receptor-mediated pathway [58,64–67]. A
distinct enzyme with a similar activity (TPP II) is located in the
cytosol, where it participates in intracellular protein degradation
and antigen processing (reviewed in [68]).
TPP I is produced as a 66-kDa inactive protein and subse-
quently activated autocatalytically by an intramolecular process
at low pH via removal of the amino terminus to form the mature
46-kDa enzyme [69,70]. The pH optimum for autoactivation
(pH ∼ 3) is lower than that of tripeptidyl aminopeptidase
activity (pH ∼ 4.5), in accord with studies showing that TPP I
has weak endoproteolytic activity at pH 3 [71]. Chemical
modification studies indicate that Ser475 is the active site
nucleophile of TPP I [69], but it lacks the classic Ser–Asp–His
of many serine proteases and lipases. Based on structural studies
of the bacterial homologs [72–74], TPP I has an unusual
catalytic triad consisting of Ser475–Asp276–Glu272 (number-
ing relative to the proenzyme) that facilitate activity at acidic
pH. This is supported by mutational analyses and inhibitor
studies [69,75,76]. The enzyme is glycosylated at most or all of
five potential asparagine-linked glycosylation sites, [77,78] and
the asparagine-linked site at position 286 is particularly
important as a naturally-occurring mutation (Asn286Ser) leads
to a poorly folded enzyme with severely reduced stability and
activity [79].
The substrate specificity of TPP I has been examined in great
detail using combinational peptide libraries [80]. Over 7,200
different fluorogenic and standard peptides were analyzed in a
systematic analysis of P3, P2, P1, P1′ and P2′ amino acid
residues (cleavage occurs between P1 and P1′). A “consensus”
sequence was not forthcoming as a number of amino acids are
tolerated at each position and there are interactions between
positions. However, some generalizations may be made. The P1
position was found to be most critical, with the large hydro-
phobic residues Leu, Phe and Nle (a stable analog of Met) being
most favored. Asn, His, Lys, Arg, Ser, Val, Ile, Thr, Gly and Pro
were highly unfavored in this position, showing less than 1% of
the activity of the best substrates. Pro, Ala, Phe, Tyr, and Trp
were favored in the P2 position. Arg was clearly preferred in the
P3 position when Phe or Leu occupied P1. The most favored
residues at P1′ were Tyr and Phe. The P2′ position accepted a
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These findings were largely, but not entirely, in agreement with
earlier studies [65,75,81].
How TPP I deficiency leads to selective neurodegeneration
of the central nervous system (CNS) is unknown, but progress is
being made in uncovering the mechanism, which is likely to be
complex. One important question to be explored is the tissue
specificity of the pathology. TPP I is widely and ubiquitously
expressed in mouse [82], rat [83,84] and human tissues [58,85–
87]. Interestingly, expression in the human brain increases with
age up to two years. Therefore, the acquisition of the adult brain
pattern of expression appears to correlate with the onset of
disease [85,86].
The storage material in CLN2 disease is not confined to the
CNS, yet the disorder disproportionately affects this organ
system. There are several possibilities as to why this may be the
case. First, it is possible that the substrate (or some downstream
metabolite) is toxic and that it is produced more rapidly in the
CNS as compared to other tissues. In addition, the CNS may
contain a specific target that is not as crucial to the function of
other tissues. Pertinent to this hypothesis is the observation that
TPP I is the predominant proteolytic enzyme responsible for the
intracellular degradation of at least one neuropeptide, neuro-
medin B [84,88,89] and plays a role in the degradation of
another, cholecystokinin [89,90] leading to the idea that in-
appropriately prolonged action of undegraded neuropeptides
plays a role. Further experimentation, such as the demonstration
of amelioration of the phenotype by agents that block their
action, is needed to confirm this hypothesis. Another possibility
is that the CNS is more vulnerable because it lacks compen-
satory enzyme activities. For example, inhibitors of TPP I can
completely block the degradation of cholecystokinin carboxy-
terminal pentapeptide by brain, whereas both inhibitors of both
TPP I and didpeptidyl peptidase I are required to block its
degradation in other tissues, suggesting that DPP I may partially
compensate for the lack of TPP I peripherally [89].
A principal protein component of storage bodies in CLN2
disease is subunit c of ATP synthase [91]. TPP I may be involved
in the degradation of subunit c as evidenced by a number of cell
culture and biochemical experiments [92,93]. CLN2 fibroblasts
accumulate subunit c, and pharmacologic inhibition of TPP I in
normal fibroblasts causes lysosomal accumulation of subunit c,
but not other mitochondrial proteins. The inhibition is overcome
by addition of TPP I. Subunit c also accumulates in other forms
of NCL (with the exception of CLN1), and in cathepsin D
deficiency [6]. It has been proposed that subunit c degradation is
initiated by TPP I, further carried out by cathepsin D, and is
especially sensitive to inhibition by elevated intralysosomal pH
[94], which is a feature of CLN2 disease shared with other forms
of NCL [95]. However, the relevance of subunit c accumulation
to the mechanism of neurodegeneration in any form of NCL
remains an open question.
1.3. CLN3 (battenin)
Mutations in the CLN3 gene underlie the juvenile type of
NCL (Batten disease, Spielmeyer–Vogt–Sjögren disease), whichis the most common form of NCL worldwide. Despite
characterization of the CLN3 gene and the corresponding protein
a decade ago [96], the function of this polytopic membrane
protein remains unknown. CLN3 protein contains 438 amino
acids and it has been located to various cellular organelles such as
lysosomes [97,98] Golgi [99,100], and mitochondria [101].
Furthermore, the protein is also detected in lipid rafts [102].
Improvements in immunological reagents have more recently
supported primarily an endosomal/lysosomal localization
[103,104]. This is also more consistent with the presence of
lysosomal storage bodies in pathologic material, including va-
cuolated lymphocytes in the peripheral blood of JNCL patients.
In neuronal cells, the protein is additionally found in the synaptic
region, indicating a possible function outside of lysosomes [105–
107]. A possible physical and functional link to mitochondria has
also remained throughout the years due to the prediction of a
conserved mitochondrial targeting sequence [108], accumulation
of a mitochondrial protein (subunit c of mitochondrial ATP
synthase), data reporting changes in morphology of mitochondria
[109], reduced ATP levels [109,110] and decreased survival
against oxidative stress [109] in JNCL cells. The CLN3 protein
has been reported to have several splice variants [111,112], but
the biological role of the variant forms remains to be solved.
Furthermore, existence of a CLN3-like protein with a homo-
logous region for 284 amino acids along the N-terminus and with
an unique, shorter C-terminus has been suggested [112].
Existence of the splice variants and the possible CLN3-like
protein could both influence the localization of CLN3 and
therefore would explain the controversial localization data.
The high conservation of the CLN3 protein from yeast to man
has enabled intensive studies of the protein in simple model
organisms. Deletion of the CLN3 homolog Btn1p in Sacchar-
omyces cerevisiae (btn1-Δ) results in resistance of the strain to
D-(−)-threo-2-amino-1-[p-nitrophenyl]-1,3-propanediol (ANP)
in a pH-dependent manner. The btn1-Δ strain shows increased
ability to acidify growth medium at the early phases of growth
and acidification of vacuolar pH, implying the functional role of
CLN3 in maintenance of vacuolar pH homeostasis [113–115].
Functional complementation of ANP resistance by human
CLN3 in btn1-Δ yeast has provided the first simple functional
test for the protein and enabled assessment of the functional
consequences of different JNCL-causing mutations [107,114].
Increased acidification of lysosomes has also been demonstrated
in cultured human embryonic kidney cells, in which the expres-
sion of CLN3was inhibited by antisense cDNA [116]. However,
alterations of vacuolar pH have been reported to be in the op-
posing direction in a fission yeast Schizosaccharomyces pombe
lacking Btn1p, which shows elevated vacuolar pH [117]. Ele-
vated lysosomal pH has also been reported in fibroblasts from
human JNCL patients [95]. Despite discrepancies between the
reported changes in vacuolar/lysosomal pH, these data have
pointed to a role for CLN3 in maintenance of pH homeostasis,
possibly via regulation of H+-transport. In fact, the vacuolar H+-
ATPase (v-ATPase) activity has been shown to be reduced in
isolated lysosomes of JNCL patents [118]. However, this phe-
nomenon is not specific for JNCL, because alterations in the v-
ATPase activity are also found in other forms of NCL [118],
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studies in a fission yeast S. pombe demonstrated that simul-
taneous removal of Btn1p and a functional v-ATPase results in
conditional synthetic lethality in yeast, suggesting a link bet-
ween the function of Btn1p and v-ATPase [117]. This functional
link was recently emphasized by the demonstration that down-
regulation of v-ATPase activity compensates for the pH changes
detected at early phases of growth in the btn1-Δ strain, implying
further that a lack of Btn1p function in S. cerevisiae results in
modulation of vacuolar H+-ATPase activity [119]. Imbalanced
pH homeostasis would explain many of the observed defects in
CLN3 deficient cells such as delayed endocytosis and abnormal
distribution of intracellular organelles [109,120]. Whether the
CLN3 protein is primarily involved in regulation of cellular pH
remains to be determined.
CLN3 is a hydrophobic membrane protein with several trans-
membrane domains. Experimental studies of the topology of
CLN3 have suggested that CLN3 contains either five or six
membrane spanning domains; the differing results derive from
discrepancies in the assignment of the N-terminus to the lumenal
[121] or cytosolic site of the membrane [103,104]. However, the
stronger evidence obtained from in vivo studies [104], and by
using a highly specific antibody against CLN3 [103], support the
six transmembrane model with the cytosolic N- and C-terminus.
CLN3 does not share any homologies among the known proteins
but the polytopic nature of CLN3 and distant relation to the family
of equilibrative nucleoside transporters, SLC29 [122] support the
view that CLN3 could have a transport/channel function (Table 1).
Evidence linking CLN3 to transport (other than H+) has
mostly been obtained from studies of S. cerevisiae. DNA micro-
array analysis of the btn1-Δ strain showed up-regulation of two
genes, HSP30 and BTN2 [115]. HSP30 encodes for a heat shock
protein that also functions as a down-regulator of the plasma
membrane H+-ATPase. Up-regulation of HSP30 in btn1-Δ can
be explained if Btn1p (and correspondingly CLN3) is involved
in maintaining the pH homeostasis in cells. BTN2 encodes for aTable 1
Suggested in vivo functions of NCL proteins
Disease Gene Protein Topology Cellular
INCL
(infantile NCL)
CLN1 PPT1
(palmitoyl protein
thioesterase 1)
soluble/
membrane
associated
lysosom
synaptic
LINCL
(late infantile NCL)
CLN2 TPP1
(tripeptidyl
peptidase I)
soluble lysosom
JNCL
(juvenile NCL)
CLN3 CLN3/battenin type III
membrane
protein
lysosom
endosom
synaptos
vLINCL (variant Finnish
late infantile NCL)
CLN5 CLN5 soluble? lysosom
vLINCL CLN6 CLN6 membrane
protein
ER
EPMR
(Northern epilepsy)
CLN8 CLN8 membrane
protein
ER
congenital/juvenile NCL CTSD cathespin D soluble lysosomnovel protein Btn2p, with high homology to mammalian Hook1
protein. Although the function of Hook proteins has mainly been
linked to membrane trafficking [123,124] the yeast Btn2p was
found to interact with Rsg1p, a negative regulator of arginine and
lysine permease Can1p [125]. Changes in the expression level of
Btn2p were shown to interfere with cellular arginine uptake
[125] suggesting alterations in the intracellular arginine levels
also in btn1-Δ cells. Further studies showed that lack of btn1 in
S cerevisiae results in deficiency of intracellular arginine and
lysine, especially in the vacuoles, implying that Btn1p may be
involved in inward transport of basic amino acids across the
vacuolar membrane [126]. Studies of basic amino acid transport
were recently expanded to include isolated lysosomes from
lymphoblast cell lines of several NCL patients. In normal
lysosomes arginine and lysine are transported by the same
transport system [127] but lysosomes from JNCL cells were
found to be defective only for arginine transport [118].
Therefore, it is unlikely that the altered pH and correspondingly,
the disturbance of membrane gradient could cause specific
alterations only in arginine transport. At present, the physiolo-
gical significance of inward directed transport of cytosolic basic
amino acids into lysosomes is unknown.
Arginine levels have also been shown to be decreased in the
serum of JNCL mice [128]. Interestingly, depletion of arginine
has been shown to lead to suppressed translation of “death pro-
teins” and consequently, to neuroprotection (reviewed in [129]).
Brain tissue from JNCL patients and mice show an increased
concentration of glutamate [130] that correspondingly predis-
poses cells to oxidative stress. Therefore it is possible that
decreased levels of arginine in JNCL correspond to cell damage
as a secondary, protective phenomenon. Arginine levels can also
be affected by several other factors such as cationic concentra-
tion rather than direct regulation of the transport across mem-
branes. In fact, recent studies in S. cerevisiae implied that altered
arginine levels may be secondary for balancing cellular ion
homeostasis since deletion of the Ist2p, a plasma membranelocalization Suggested functions in vivo
es
vesicles
*lysosomal degradation of acylated proteins (determined in
vitro substrates; H-Res, palmitoyl-CoA, subunits of modified
Gα proteins) *regulation of pH *regulation of inflammatory
response *quantitative regulation of the synaptic vesicles pool
*antiapoptotic function
es *lysosomal degradation of proteins (in vitro determined
substrates; neuromedin B, subunit c of mitochondrial ATP
synthase, cholecystokinin) *antiapoptotic function
es/
es/
omes
*maintenance of lysosomal pH homeostasis *inward lysosomal
arginine transport *role in membrane tracking *antiapoptotic
function (may occur via modulation of ceramide synthesis)
es *unknown
*unknown
*lipid synthesis, transport, sensing
es *bulk protein degradation
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suppress the defect in vacuolar arginine transport in the btn1-Δ
strain [131]. Since neither Btn1p nor CLN3 has been shown to
directly interact with any of the transporters/channels, the func-
tional role of CLN3 in regulation of ion transport still remains
speculative.
Due to the hydrophobic nature and relatively low expression
level of the CLN3 protein, screening for direct interaction part-
ners has been difficult. The full length CLN3 has been shown to
interact with another lysosomal NCL protein, CLN5 [132].
However, the CLN5 protein is currently poorly characterized
and therefore, the significance of this interaction is still un-
known. Experimental knowledge of the topology of the protein
[103,104,121,133] has enabled the screening of interacting
proteins by using separate domains of CLN3. CLN3 has been
shown to interact with the trafficking adaptors AP-1 and AP-3
via its dileucine motif [134] but controversial data about these
interactions have also been presented [133]. CLN3 contains a
second, unusual targeting motif (MX9G) in the cytoplasmic tail
[104] suggesting that localization, and possibly, the function of
the protein may be regulated by variable recognition of multiple
targeting signals by the cellular transport machinery.
CLN3 was also shown to weakly interact with mammalian
Hook1 protein via both the N-terminus and the cytosolic loop
domain. Simultaneous overexpression of CLN3 with Hook1
results in relocalization of Hook1 into large aggregates suppor-
ting the functional connection between the two proteins [120], as
suggested by the earlier yeast microarray analysis [115]. The
function of the microtubule-binding Hook proteins in mamma-
lian cells is not well understood, butDrosophilaHook1 has been
shown to be involved in directing internalized ligands to late
endosomes or multivesicular bodies [123,124]. Luiro et co-
workers [120] showed that mammalian Hook1 interacts with
several Rab proteins, the small GTPases associated with en-
dosomal compartments along the endocytic pathway. This fin-
ding strongly suggests that CLN3 could have at least an indirect
role in membrane trafficking, possibly by regulating vesicular
transport and/or fusion. Of note, abnormalities in both the fluid-
phase and receptor-mediated endocytosis have been observed in
JNCL cells [109,120]. Furthermore, fast axonal transport of
amino acids in the optic nerve of JNCL mouse was recently
shown to be decreased [135]. If CLN3 plays a role in endocytic
vesicular trafficking, then it may function not only in the ly-
sosomes but also in the earlier endocytic compartments. These
findings are consistent with the localization of CLN3 to endo-
cytic organelles both in non-neuronal [97,100,103] and neuronal
cells [104]. Furthermore, trafficking of Btn1p in S. pombe to
vacuoles has been shown to be relatively slow and dependent on
Ras GTPase Ypt7p, the protein required for vacuolar fusion
[117]. Deletion of ypt7 (ypt7Δ) results in restriction of Btn1p
trafficking to pre-vacuolar compartments. However, Btn1p is
able to modify the vacuolar size and the pH in ypt7Δ from the
pre-vacuolar compartment, since double deletion of the btn1 and
ypt1 increases the vacuolar phenotype over that seen in ypt7Δ
alone [117].
Mammalian Hook proteins have been shown to interact with
microtubules [136]. The yeast Btn2p (a homologue of mam-malian Hook1) has also been shown to interact with ankyrin G,
an adaptor protein connecting integral membrane proteins with
spectrin-based membrane cytoskeleton [137]. Ankyrin proteins
play an important role in many cellular functions such as
membrane skeletal organization and ionic transport (reviewed in
[138]). Therefore, the function of CLN3 may also be related in
some way to the cytoskeleton. As a vesicular membrane protein,
CLN3 may be required for unimpeded vesicular movement
along microtubules. Impaired axonal transport has been shown
to be an important factor contributing to neurodegeneration in
many disorders (reviewed in [139]). Furthermore, ion transport
is also tightly linked to cytoskeletal interactions. Therefore it is
possible that the detected alterations in lysosomal pH and in
arginine transport in JNCL cells result from disturbed connec-
tions between CLN3 and the cytoskeleton.
The function of CLN3 has also been approached by inves-
tigating cell death in JNCL patients and mice. Both apoptosis
and autophagy have been implicated in this process [3,140–
142]. Decreased expression of CLN3 has been shown to corre-
late with sensitivity of cultured cells to undergo apoptotic cell
death [143]. Correspondingly, overexpression of CLN3 has
been reported to enhance cell growth in cultured cells and to
protect cells from induced apoptosis provoked by diverse sti-
muli [144]. Recent data suggest that the protective role of CLN3
in cell death may occur through modulation of the generation of
ceramide, which induces both caspase-dependent and caspase-
independent cell death [142]. Interestingly, the expression of
CLN3 is increased in several types of cancer [145], but the
functional importance of this phenomenon remains to be
determined.
1.4. CLN5
The Finnish variant late infantile form of NCL is caused by
mutations in the CLN5 gene, mapped to chromosome 13q22.
The gene consists of 4 exons, spanning 13 kb of genomic DNA,
and encodes a protein of 407 amino acids. Three transcripts of
the human CLN5 gene of 2.0, 3.0 and 4.5 kb have been detected
[146]. The predicted amino acid sequence of CLN5 shows no
homology to previously reported proteins. Whereas transfection
of COS-1 cells with CLN5 cDNA results in the synthesis of a
highly glycosylated soluble 60 kDa polypeptide, in cell-free
translation assays 47, 44, 42 and 40 kDa polypeptides were
produced due to usage of alternative initiator methionine codons
[147]. Immunofluorescence microscopy and proteomic studies
analyzing purified mouse lysosomes revealed that CLN5 is
transported in a mannose 6-phosphate-dependent manner to ly-
sosomes [147,148]. The function of the CLN5 protein is not
known. The major storage component in CLN5 tissues is sub-
unit c of the mitochondrial ATP synthase [149]. Co-immuno-
precipitation and in vitro binding assays showed that CLN5
interacts directly with CLN2 and CLN3 polypeptides, without
affecting the tripeptidyl peptidase (TPP) activity of CLN2
[132].
The mouseCln5 gene encodes a predicted polypeptide of 341
amino acids that undergoes cleavage of a 3 kDa signal sequence.
Amajor transcript of 2.9 kb and a minor transcript of 2.3 kb have
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[150]. Interruption of the Cln5 gene in a genetically engineered
mouse model resulted in a syndrome resembling symptoms of
human CLN5 without prominent brain atrophy [151]. However,
a loss of GABAergic interneurons in several brain areas was
detected in the affected mice as reported also for other NCL
models [1]. Gene expression profiling in CLN5-defective brain
showed up-regulation of inflammation-associated genes, and
down-regulation of myelin-associated genes, supporting patho-
logical findings of hypomyelination in CLN5 patients. The
molecular changes in these affected mice may allow the iden-
tification of specific pathomechanism contributing to neurode-
generation and help to find neuropathological changes in all
NCL disorders.
1.5. CLN6
The variant late infantile form of NCL is caused by mutations
in the CLN6 gene. This gene is located on chromosome 15q23,
and spans ∼ 22.7 kb containing seven exons, which produces a
single 2.4 kb mRNA [152,153]. The highly conserved protein
encoded by the CLN6 gene contains 311 amino acids and loca-
lizes to the endoplasmic reticulum (ER) [154,155]. CLN6 con-
tains an N-terminal cytoplasmic domain, an odd number (most
likely 7) of transmembrane domains, and a luminal C-terminus
(C. Heine, unpublished). CLN6 contains no asparagine-linked
glycosylation sites and can form dimers upon overexpression
[154]. The function of the CLN6 protein is unknown. Analysis
of fibroblast cells from CLN6 patients or animal models of the
disease have documented that the transport, sorting and
processing of newly synthesized lysosomal protease cathepsin
D is not affected by defective CLN6. In contrast, mutant CLN6
results in an increased mannose 6-phosphate receptor-depending
uptake of the recombinant lysosomal enzyme arylsulfatase A
and its reduced intracellular degradation [154]. The latter might
be related to the finding that the intralysosomal pH is increased
in CLN6 patient fibroblasts [95].
There are naturally occurring animal models for CLN6; the
nclf mouse caused by a single-base insertion in exon 4 (c.316
dupC), and the South Hampshire sheep, developing clinical
symptoms closely resembling human CLN6 [91,152,156].
These animal models provide valuable tools for the study of
pathogenic mechanisms. The mice are clinically normal until 8–
9 months of age at which time they become paralysed followed
by premature death in an age of about 1 year. The mice also
exhibit a slowly progressing retinal degeneration. The storage
material in CLN6-defective cells is largely composed of auto-
fluorescent material in lysosomes that has been identified as the
subunit c of the mitochondrial ATP synthase [157]. This hydro-
phobic proteolipid is most likely transferred to lysosomes
through an autophagic process. There is, however, a lack of
association between storage material accumulation and neuro-
degeneration [1]. Recently, activated astrocytes and focal clus-
ters of activated microglia were detected in presymptomatic
affected sheep [158], which might be part of a stress response
causing cell loss, or might be an indicator of an attempted pro-
tective process to suppress mechanisms leading to neuronaldamage at early stages of pathogenesis of CLN6 as well as in
several other lysosomal storage disorders [38,39]. Furthermore,
elevated expression of the mitochondrial matrix radical sca-
venger protein, manganese-dependent superoxide dismutase
(MnSOD) has been reported in affected brain tissue [159], which
might be a consequence to an increased oxidative burden or an
activation of glial cytokine production. Both reactive oxygen
species (ROS) and a variety of pro-inflammatory mediators are
important for regulation of MnSOD expression [160,161]. Gene
array and protein analysis of cultured hippocampal neurons from
nclf mice has revealed a significant reduction in GABA α2
receptor (A. Quitsch, C. Heine, J. Tyynelä, C. von Schantz, A.
Jalanko, T. Braulke, unpublished results) suggesting a dysfunc-
tion of GABAergic neurons which appears to be a typical
neuropathological hallmark of several NCLs [1].
In conclusion, defects in the ER resident membrane protein
CLN6 result in lysosomal dysfunction, which initiates several
pathogenic processes leading to progressive neurodegeneration.
Determination of the reason for the impaired lysosomal meta-
bolism may help to clarify CLN6 function and deserves further
investigation.
1.6. CLN8
Mutations in the CLN8 gene underlie progressive epilepsy
with mental retardation, EPMR [162–164]. CLN8 is an ubi-
quitously expressed 33 kDa non-glycosylated membrane protein
that resides in the ER and the ER–Golgi intermediate compar-
tment (ERGIC) both in non-neuronal and neuronal cells.
Currently, the function of CLN8 is not known. Inactivation of
its dilysine-based ER-retention signal results in an altered loca-
lization in post-ER compartments, mainly in the Golgi complex
[165–167]. However, known patient mutations do not interfere
with the ER localization of CLN8.
By sequence homology, CLN8 is related to a large eukaryotic
protein family of TLC-domain homologues (TRAM, Lag1,CLN8
homology domain; SMART accession number SM00724) with
postulated functions in lipid synthesis, transport or sensing [168].
Members of this family have been shown to facilitate translocation
of nascent polypeptide chains into the ER and export of glyco-
sylphosphatidylinositol-anchored proteins out of the ER [169–
171]. Proteinswithin this family sharemodest identity at the amino
acid level but have a conserved domain structure with at least five
transmembrane α-helixes and few highly or absolutely conserved
amino acid residues. Recent reports specify a role for TLC-proteins
in the regulation of acyl-CoA dependent ceramide synthesis in
yeast [172,173] and mammalian cells [174–176]. Interestingly, a
novel NCL-phenotype, CLN9, characterized by decreased sphin-
golipid levels, could be partially corrected by transfecting TLC-
homologues including several LASS cDNAs that encode human
dihydroceramide synthases, but also with CLN8 [177,178]. This
suggests that CLN8 and CLN9 might be functionally related and
operate in the regulation of ceramide synthesis.
Whether CLN8 could have catalytic activity or a regulatory
function in (sphingo)lipid metabolism remains still to be demon-
strated. However, mass spectrometric analysis of cerebral samples
of two EPMR cases has revealed changes in the molecular
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EPMR progresses, the proportion of long-chain fatty acyl-contai-
ning sphingolipids (especially ceramide and sphingomyelin
species) declines, but long-chain polyunsaturated glyceropho-
spholipids increase. An increase in polyunsaturated fatty acids,
which are susceptible to oxidative damage, together with an
observed reduction in plasmalogens, which act as endogenous
antioxidants, may lead to increased lipid peroxidation and forma-
tion of lipofuscin, thereby promoting the progression of EPMR. In
advanced stages of EPMR, the proportion of polyunsaturated fatty
acid, especially docosahexaenoic acid (DHA) containing phos-
pholipids was dramatically decreased, as seen in CLN1 [180], and
sphingolipids accumulated. These compositional changes might
lead to altered membrane properties, but also have specific effects
on the function of membrane receptors, transporters and ion
channels.
Lipid metabolism also appears be perturbed in the mnd (motor
neuron degeneration) mouse, the naturally occurring mouse model
for EPMR [181]. Reduced activities of enzymes involved in
phospholipid biosynthesis due to abnormalities in ER-related mito-
chondria-associated membranes have been reported in mnd liver
[182]. NMR spectroscopy reveals accumulation of lipid in cere-
brum of the mnd mouse, but also an increased ratio of CH2CH2-
CH2/CH2CH3 and CH_CH lipid moieties, indicating longer fatty
acyl chain length and a higher degree of unsaturation [183].
Increased oxyradicals and lipid peroxides indicate that oxi-
dative metabolism is also altered in themndmouse [184,185]. In
addition, decreased activities in several mitochondrial respira-
tory complexes have been measured in the spinal cord [184].
Altered mitochondrial membrane properties were also suggested
to impact changes in oxidative metabolism, because a reduction
in total oxygen consumption was more prominent than could be
deduced from enzymatic activities.
Although no general alterations in neurotransmitter release or
uptake have been detected, glutamatergic neurotransmission
appears specifically affected in the mnd mouse. Decreased sy-
naptosomal glutamate uptake and reduction of the GLT-1 and
EAAC1 glutamate transporters [186,187] might underlie increased
cerebral and spinal glutamate concentrations [183,188]. An
increased expression of glutamate receptor subtypes, notably
GluR2, has been detected in presymptomatic mice, implying that
changes in glutamate excitation may contribute at an early stage to
motor neuron degeneration in the mnd mouse [188].
Changes in lipid metabolism observed in EPMR patients and
the mnd mouse might predispose especially cells in the central
nervous system to oxidative challenge but also by affecting
membrane properties contribute to altered release and uptake of
neurotransmitters. Although sequence analysis suggests a role for
CLN8 in cellular lipid homeostasis, modulation in lipid composi-
tionmight still be a secondary event to compensate yet unidentified
primary defects caused by mutations in the CLN8 protein.
1.7. Cathepsin D
Several animal models has been described with mutations in
the cathepsin D gene (CTSD) exhibiting symptoms of a severe
congenital NCL, such in White Swedish Landrace sheep [5], orwith less severe late-onset NCL in American Bulldogs [7].
Targeted disruption of the Ctsd gene in mice and Drosophila,
however, results in an early-onset NCL phenotype and with
prominent neuropathological changes in the CNS and retina
[6,189–191]. Very recently, the first NCL patients with
mutations in the CTSD gene were described with clinical and
neuropathological findings compatible with congenital NCL
who died at 1 to 10 days of age [8], or with a severe course of
neurodegeneration beginning at early school age [9].
The human CTSD gene is located on chromosome 11p15.5,
contains 9 exons, and encodes a protein of 412 amino acids.
Transcription of the gene is initiated from several sites including
one that is a start site for an estrogen-regulated transcript [192].
CTSD is a major lysosomal aspartic protease and is related to
other aspartic proteases such as renin, pepsin and yeast
proteinase A [193]. Human CTSD is synthesized in the ER as
a 53-kDa inactive preproenzyme, which undergoes several
posttranslational modifications during transport to lysosomes.
Following co-translational cleavage of the N-terminal signal
peptide, pro-CTSD becomes glycosylated at two N-linked
glycosylation sites and equipped with mannose 6-phosphate
residues, allowing mannose 6-phosphate receptor-mediated
segregation from the secretory route. Upon arrival in the acidic
endosomal compartment, proteolytic cleavage of the N-terminal
44-amino acid propeptide results in the formation of an active
single chain 47-kDa intermediate form of CTSD [193–197].
Final proteolytic maturation, resulting in the formation of a
disulfide-linked double chain 31- and 14-kDa polypeptide, is
completed in lysosomes and depends on cysteine proteinases
[195,198]. It has been suggested that the single- to double-chain
conversion of human CTSD is accompanied by the release of
six amino acid residues between the chains [199]. Rat and
mouse Ctsd exist predominantly as a single-chain molecule.
Depending on the cell type, lysosomal targeting of CTSD
occurs in a mannose 6-phosphate-dependent or -independent
manner, resulting in variable sorting efficiency in the trans
Golgi and subsequent secretion [200].
Crystallographic studies have shown that CTSD is a bi-lobed
molecule with the active site cleft located between the lobes,
with each lobe contributing an aspartic acid residue to the
catalytic center. At the optimum pH of 2 to 3, one aspartate is
ionised whereas the second one is not [201]. CTSD is involved
in limited proteolysis rather than in bulk proteolysis [190].
There are several proteins described to function as substrates of
CTSD in vitro whereas the in vivo substrates are still unknown.
The accumulated material of undigested substrates, including
subunit c of mitochondrial ATP synthase in the lysosomes of
neurons of Ctsd-deficient mouse brains, is immunoreactive for
LC3-II, a marker for autophagosomes [11]. Autophagy is a
regulated process involving the bulk degradation of cytoplasmic
macromolecules and organelles. Furthermore, autophagosomes
have been observed in perikarya and also in axons of neurons;
these structures may contribute to the formation of meganeurites
and their presence suggests that retrograde axonal transport is
impaired. These data therefore argue for induction of autophagy
and its involvement in the pathogenesis of cathepsin D-related
NCL.
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How might proteins located in different subcellular
compartments result in similar types of disorders, and how
can the specific vulnerability of neurons in NCLs be accounted
for? All characterized NCL proteins are located in the
endosome/lysosome pathway, and it is possible that the
trafficking and correspondingly, the correct localization of
different NCL proteins, are dependent on interactions between
the different proteins. However, lack of any one of the NCL
proteins does not result in severe mislocalization of other NCL
proteins (Kyttälä et al., unpublished observations). Therefore, it
is possible that deficiency of one NCL protein may either
directly or indirectly lead to functional consequences upon
another NCL protein by interfering with another phenomenon
apart from cellular localization. In fact, such findings have
already been reported. Both the activity and the amount of
mannose 6-phosphorylated TPP1 (CLN2) has been shown to be
increased in the other forms of NCL (although this may not be
specific to NCLs, since TPP1 activity is also increased in
Alzheimer's disease) [202]. Furthermore, it has been suggested
that the sequential action of TPP1 and cathepsin D are required
for the lysosomal degradation of the subunit c of the
mitochondrial ATP synthase in a pH dependent manner [94].
Therefore any change in cellular pH homeostasis, which has
been reported in many NCLs [95] would result in abnormal
accumulation of subunit c. Whether the findings of elevated
level of mature forms of cathepsin D in CLN3 antisense
expressing HEK 293 cells [116], the reduced steady state
concentration of mature cathepsin D in cerebellar neurons of
Cln3Δex7/8 mice [109], or the unaltered processing of cathepsin
D in vLINCL (CLN6) [154] can be correlated to changes in
lysosomal pH remain to be investigated. In addition, CLN8 can
partially rescue the perturbed sphingolipid metabolism detected
in CLN9-deficient cells [178], indicating that CLN8 and the so
far unidentified CLN9 may share functions in regulation of
ceramide synthesis.
One of the fundamental questions in NCL research field is
the selective cell death of neurons in NCL. Apoptosis has been
suggested to be one mechanism of cell death in NCLs [3] and
many NCL proteins have been shown to have anti-apoptotic
properties in vitro [43,144,203]. Increasing evidence suggests
that autophagy could also play an important role in disease
pathogenesis [3,11,142]. In fact, it has been shown elsewhere
that inhibition of autophagy by 3-methyladenine in cultured
fibroblasts results in accumulation of the lipofuscin-like
material [204]. Therefore, it is tempting to hypothesize that
autophagic pathways are involved in the development of NCL,
as this could explain the accumulation of subunit c protein of
mitochondrial ATP synthase in most forms of NCL.
Very little is currently known concerning proteins that might
directly interact with different NCL proteins. CLN5 has been
shown to interact with both CLN2 and CLN3 but the importance
of these interactions remains to be determined [132]. The know-
ledge of interacting proteins combined with data from high
throughput screening techniques (such as microarray analyses,
proteomics and metabolic profiling) and detailed pathologicalanalyses of NCL model organisms will be crucial in moving
toward a functional understanding of these proteins.
Despite the fact that the precise biological functions of all NCL
proteins are still elusive, determination of the secondary con-
sequences of defects inNCLproteins also provides important data
that may facilitate therapeutic approaches. Determination of the
primary functions of different NCL proteins and the knowledge of
the biological pathways they are functionally connected will help
to understand not only the disease pathology of NCLs but may
also provide answers to more fundamental questions such as
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